Halozyme signs collaboration deal with GSK for oncology targets
Halozyme Therapeutics has entered into a global collaboration and license agreement with GSK to develop subcutaneous formulations of multiple oncology targets, including antibody drug conjugates, using Halozyme's ENHANZE drug delivery technology. The deal involves an upfront payment, potential future milestone payments, and royalties for Halozyme, with the first clinical trial projected for 2026. This collaboration marks Halozyme's first ENHANZE agreement for antibody drug conjugate targets and reflects the company's strong financial momentum and strategic efforts to expand its technology's reach.
Price to sales forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO
This article provides financial information for Halozyme Therapeutics, Inc. (NASDAQ: HALO), specifically focusing on its price-to-sales forward metric. It appears to be a stub or partial financial data page from TradingView, offering a snapshot of the company's valuation.
Halozyme Therapeutics (HALO) Leadership Reset Raises The Question Of Whether The Stock Is Fully Valued
Halozyme Therapeutics (HALO) has undergone a leadership reshuffle, including the appointment of a new President of Drug Delivery and a COO departure, aiming to refocus on core drug delivery activities. With the stock performing well, trading at US$79.45, the article questions whether the market has fully priced in these changes and the potential growth from diversified royalty streams. While a narrative suggests the stock is 7.4% undervalued based on long-term cash flow, its P/E ratio is higher than the biotech industry average, posing a valuation risk.
Halozyme Therapeutics (HALO) Leadership Reset Raises The Question Of Whether The Stock Is Fully Valued
Halozyme Therapeutics (HALO) has undergone significant leadership changes, including the appointment of a new President of Drug Delivery and the departure of its COO, signaling a refreshed focus on its core drug delivery activities. These changes coincide with strong stock performance, with a 1-month return of 13.79% and a 1-year return of 47.13%, prompting questions about whether the stock is fully valued. While a discounted cash flow narrative suggests the stock is 7.4% undervalued, trading at a P/E of 27x compared to the industry average of 16.8x indicates potential valuation risk.
Halozyme (HALO) director sells 1,625 shares in 10b5-1 trades
Halozyme Therapeutics, Inc. (HALO) director Bernadette Connaughton sold a total of 1,625 shares of common stock in two open-market transactions. These sales were executed at weighted average prices of approximately $76 to $77 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 29, 2025. This indicates the transactions were part of scheduled portfolio management rather than discretionary timing.
Halozyme (NASDAQ: HALO) EVP receives new options, RSUs and RSU vesting
Halozyme (NASDAQ: HALO) EVP David A. Ramsay was granted 39,823 stock options at $77.01 per share and 16,232 Restricted Stock Units (RSUs) on July 1, 2026, as part of his compensation. Additionally, 10,000 RSUs vested on June 30, 2026, with a portion withheld for tax obligations, resulting in 4,592 shares directly owned by Ramsay. These transactions are routine equity awards and vesting events, not open-market trades.
Halozyme stock falls as chief operating officer departs
Halozyme Therapeutics Inc. (NASDAQ:HALO) shares dropped 3.1% in after-hours trading following the announcement that its COO, Cortney Caudill, is departing the company. Caudill's exit is effective June 30, 2026, and was disclosed in an 8-K filing, which did not provide reasons for her departure or plans for a replacement.
Halozyme Therapeutics Operating Chief Caudill to Exit
Halozyme Therapeutics announced that its Chief Operating Officer, Nicole Laakso Caudill, will be leaving the company effective July 19. Caudill's departure is part of a planned transition as the company evolves. She will continue to serve as a consultant until September to ensure a smooth handover.
Halozyme (NASDAQ: HALO) CFO awarded large option and RSU package
Halozyme Therapeutics' CFO, Darren Snellgrove, was granted substantial equity awards on July 1, 2026, including options to purchase 127,432 shares at an exercise price of $77.01 and 41,554 restricted stock units (RSUs). These compensation-related grants are designed to incentivize long-term commitment, with options vesting over four years and RSUs over three years. This increases his potential future ownership, aligning his interests with shareholder value.
Halozyme Therapeutics (HALO) COO Cortney Caudill to depart in management reshuffle
Halozyme Therapeutics, Inc. announced a senior management reshuffle, including the departure of Cortney Caudill, Senior Vice President and Chief Operating Officer, effective June 30, 2026. The company expressed gratitude for her contributions during her tenure. This change was reported in an 8-K filing to the SEC, highlighting a key personnel change within the organization.
Is Halozyme (HALO) Elevating Drug Delivery Leadership to Reframe Its Core Investment Narrative?
Halozyme Therapeutics has appointed David Ramsay as President, Drug Delivery, a new role intended to scale its drug delivery partnerships and alliances. This move intensifies focus on their ENHANZE platform, which is crucial for attracting and expanding high-value collaborations. While the company forecasts significant revenue and earnings growth by 2029, investors are cautioned about the concentration risk in a few blockbuster deals and potential pricing pressures.
Form 4 Halozyme Therapeutics Inc For: 30 June By Investing.com
This article announces the filing of a Form 4 for Halozyme Therapeutics Inc., covering the period up to June 30. It provides this information alongside a live market data feed for various global indices, commodities, and individual stocks. The brief news piece includes the stock symbol HALO and notes a 3.17% increase.
Press Release: Halozyme Appoints David Ramsay as President Drug Delivery
Halozyme has announced the appointment of David Ramsay as President, Drug Delivery. Ramsay, who previously served as Chief Commercial Officer, will now lead the company's ENHANZE® drug delivery technology business. This strategic move aims to strengthen Halozyme's focus on its core drug delivery platform.
Halozyme names David Ramsay as president drug delivery By Investing.com
Halozyme Therapeutics, Inc. has appointed David Ramsay as President of Drug Delivery, a newly created role where he will oversee the growth and business development of the company's drug delivery technologies. Ramsay, who has a long history with Halozyme including multiple stints as CFO, brings over 30 years of experience in strategic financial leadership. This appointment follows strong financial results for Q1 2026, with earnings and revenue exceeding expectations, and positive analyst ratings affirming the company's robust position.
Form 4 Halozyme Therapeutics Inc For: 30 June By Investing.com
This article reports on a Form 4 filing for Halozyme Therapeutics Inc., covering the period up to June 30. Form 4 filings are used to disclose changes in beneficial ownership of securities by company insiders. The article notes Halozyme Therapeutics Inc.'s stock symbol as HALO, which experienced a 1.39% increase at the time of publication.
Halozyme names David Ramsay as president drug delivery By Investing.com
Halozyme Therapeutics, Inc. has appointed David Ramsay as President Drug Delivery, a newly created role where he will oversee the growth of the company's drug delivery technologies. Ramsay brings over 30 years of experience in strategic financial leadership and has previously served in various capacities at Halozyme, including Interim Chief Financial Officer and Chief Financial Officer. The company, which specializes in ENHANCE drug delivery technology, has shown strong financial performance and is considered undervalued by InvestingPro analysis.
Halozyme director Mahesh Krishnan sells $547,800 in stock By Investing.com
Halozyme Therapeutics director Mahesh Krishnan sold 7,304 shares of common stock for $547,800 after exercising options. The sale was executed via a pre-arranged trading plan, as the stock approaches its 52-week high and is considered undervalued by InvestingPro. This transaction follows recent company news including a new executive appointment and positive analyst outlooks on Halozyme's financial performance and ENHANZE technology.
Halozyme (HALO) director exercises options, sells 7,304 shares under plan
Halozyme Therapeutics, Inc. (HALO) director Mahesh Krishnan exercised options for 7,304 shares at $38.46 per share and subsequently sold all 7,304 shares on the open market at $75.00 per share. These transactions, valued at approximately $548,000, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026. After the sale, Krishnan holds 14,462 common shares and 1,500 options.
Halozyme Appoints David Ramsay as President Drug Delivery
Halozyme Therapeutics, Inc. announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026. In this new role, Ramsay will be responsible for driving the growth of Halozyme's drug delivery technologies and establishing strategic priorities. This appointment follows his recent tenure as Interim Chief Financial Officer and previous roles including CFO and VP of Corporate Development at Halozyme.
[144] HALOZYME THERAPEUTICS, INC. SEC Filing
This article reports on a Form 144 SEC filing by HALOZYME THERAPEUTICS, INC. The filing, accepted on June 29, 2026, details a proposed sale of securities under Rule 144. It includes information about the filer, issuer, and the specifics of the securities to be sold, such as the number of shares and their acquisition details.
ETFs Investing in Halozyme Therapeutics, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Halozyme Therapeutics, Inc., providing detailed financial metrics for each ETF. It includes information such as market value, weight, issuer, management style, expense ratio, assets under management (AUM), price, and 3-year NAV total return. The ETFs cover different market segments like mid-cap, small-cap, total market, and specific sectors like healthcare and biotechnology.
Price to sales forward of Halozyme Therapeutics, Inc. – BMV:HALO
This article provides the "Price to sales forward" metric for Halozyme Therapeutics, Inc. (HALO) on the Mexican Stock Exchange. The current overview shows the market as closed with no trades.
Price to sales forward of Halozyme Therapeutics, Inc. – FWB:RV7
This article provides the "Price to sales forward" metric for Halozyme Therapeutics, Inc. (FWB:RV7) on the TradingView platform. It indicates that the market is currently closed with no trades recorded for this particular period.
Halozyme Therapeutics, Inc. Actuals & Estimates (NASDAQ:HALO)
This article provides a detailed overview of Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock performance, financial actuals and estimates, and analyst forecasts. It covers key metrics such as current stock price, historical highs and lows, market capitalization, earnings, revenue, and EBITDA, along with investment advice and future outlook.
Halozyme Therapeutics, Inc. Actuals & Estimates (FWB:RV7)
This article provides an overview of Halozyme Therapeutics, Inc. (FWB:RV7) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's recent earnings beat, revenue figures, market capitalization, and upcoming earnings report date.
Enterprise value to revenue forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO
This article provides the enterprise value to revenue forward for Halozyme Therapeutics, Inc. (NASDAQ: HALO). It appears to be a stub or a data point from TradingView, indicating financial information for the biotechnology company. The page structure suggests it's part of a larger financial data platform.
Enterprise value to revenue forward of Halozyme Therapeutics, Inc. – TRADEGATE:RV7
This article displays the forward enterprise value to revenue for Halozyme Therapeutics, Inc. (TRADEGATE:RV7) on TradingView. It indicates that the market is currently closed with no trades. The article provides a snapshot of the stock's financial overview on the platform.
Price to book forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO
This article provides the "Price to book forward" financial metric for Halozyme Therapeutics, Inc. (NASDAQ: HALO). It appears to be a direct data output from a financial platform like TradingView, with no additional textual analysis or details provided. The content focuses solely on this specific financial ratio for the company.
Did Expanding ENHANZE Partnerships and Cash Generation Just Shift Halozyme Therapeutics' (HALO) Investment Narrative?
Halozyme Therapeutics' investment narrative is being influenced by its expanding ENHANZE partnerships and strong cash generation. The company, through its ENHANZE technology, collaborates with major pharmaceutical companies to enable subcutaneous delivery of biologic drugs, bolstering its position as a platform provider. While growth in partnerships and cash flow supports the core thesis, the valuation remains dependent on a limited number of high-volume therapies.
Did Expanding ENHANZE Partnerships and Cash Generation Just Shift Halozyme Therapeutics' (HALO) Investment Narrative?
Halozyme Therapeutics' investment narrative is being reinforced by expanding partnerships for its ENHANZE technology and strong cash generation. While these developments support the core thesis that ENHANZE will remain a preferred method for subcutaneous biologic delivery, investors should still be aware of the company's dependency on a relatively small number of high-volume therapies for its valuation. Upcoming collaborations and financial projections suggest significant revenue and earnings growth, though some analysts retain caution regarding long-term relevance and pricing power.
Halozyme Therapeutics Inc (HALO) Institutional Confidence
Halozyme Therapeutics Inc (HALO) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. Institutional shareholding increased by 10.45% quarter-over-quarter, with 117.14% of shares held by institutions. The largest institutional shareholder is Bill Nygren | OAKMX, holding 0.63% of outstanding shares.
Halozyme Therapeutics (HALO) Stock Could Be 18.8% Undervalued As Partner Growth Lifts Sentiment
Recent commentary on Halozyme Therapeutics (HALO) focuses on its collaborations with large pharmaceutical partners and its use of recombinant human hyaluronidase technology. The company's stock shows a 10.07% 90-day return and a 31.03% 1-year total shareholder return. Despite potential undervaluation by 18.8% based on a fair value estimate of $85.78, its P/E ratio of 23.7x is above the US Biotech industry average.
What Halozyme Therapeutics (HALO)'s New ENHANZE Partner Data and Analyst Support Means For Shareholders
Halozyme Therapeutics received a boost from positive clinical data reported by partner argenx for a therapy using Halozyme's ENHANZE drug delivery technology, coupled with a reaffirmed positive analyst rating. This reinforces the strength of Halozyme's licensing model, which is heavily reliant on partner success to meet its 2026 revenue guidance and achieve projected future growth. Investors should be aware of the concentration risk associated with its reliance on a few key partners.
Halozyme Therapeutics (HALO) Stock Could Be 18.8% Undervalued As Partner Growth Lifts Sentiment
Halozyme Therapeutics (HALO) is featured as potentially undervalued by 18.8%, trading at $69.64 against a fair value estimate of $85.78, primarily due to its royalty engine and ENHANZE platform, which benefits from the shift to subcutaneous drug delivery. While analyst sentiment is positive regarding long-term growth and margin expansion, risks include revenue concentration and patent challenges. The article also notes that HALO's P/E ratio of 23.7x is higher than the US Biotechs industry average, indicating a premium valuation despite the intrinsic undervaluation.
Halozyme Therapeutics Inc (HALO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a detailed breakdown of Halozyme Therapeutics Inc.'s (HALO) revenue by business segments and geographical regions. As of April 6, the company's revenue primarily comes from royalties (62.14%) and sales of proprietary products (13.93%). Regionally, the United States accounts for the largest share (58.93%).
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $95
H.C. Wainwright has reiterated its Buy rating for Halozyme Therapeutics (HALO.US) and maintained a target price of $95. This indicates a continued positive outlook from the analytical firm regarding the company's stock performance.
Halozyme (HALO) CLO reports RSU vesting and share withholding for taxes
Halozyme Therapeutics' SVP and Chief Legal Officer, Mark Howard Snyder, reported routine equity compensation activity. 5,034 restricted stock units (RSUs) vested and converted into common shares on June 12. To cover tax obligations, 2,715 shares were withheld by the company at a market price of $69.50 per share, which is a standard procedure and not an open-market sale. Following these transactions, Snyder directly owns 49,929 shares of HALO common stock.
(HALO) Volatility Zones as Tactical Triggers
This article analyzes Halozyme Therapeutics Inc. (NASDAQ: HALO) using AI models to provide tactical triggers based on volatility zones. It highlights a neutral near-term sentiment with strong mid-term sentiment potentially stalling, and identifies support and resistance levels. The analysis offers three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and a strong risk-reward setup.
Halozyme sees minimal impact from Medicare drug pricing rule
Halozyme Therapeutics Inc. expects minimal to zero impact on its royalty revenue through at least 2035 from the proposed Medicare Drug Price Negotiation Program rule, according to its analysis. This outlook is based on provisions in the rule that preserve orphan drug protections and consider the impact of biosimilar entry. The company also anticipates no effect on its ability to secure new ENHANZE partnership agreements for its drug delivery technology.
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
Halozyme Therapeutics, Inc. announced its analysis of the proposed Medicare Drug Price Negotiation Program rule, projecting zero to minimal impact on its royalty revenue through at least 2035. The company also states there is no projected impact on its ability to sign new ENHANZE® partnership agreements. This outlook is supported by safeguards for orphan drugs and biosimilar entry impacts, and Halozyme plans to continue engaging with CMS to support innovation and patient access.
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
Halozyme Therapeutics (HALO) shares have increased by 0.8% since its last earnings report, outperforming the S&P 500. The company reported strong first-quarter 2026 results, with adjusted earnings of $1.60 per share and total revenues of $376.7 million, both surpassing Zacks Consensus Estimates. Despite a downward trend in recent estimate revisions, Halozyme maintains a Zacks Rank #3 (Hold) and strong growth prospects for 2026.
Halozyme Therapeutics (HALO) CFO files Form 3 insider ownership statement
Halozyme Therapeutics (HALO) Senior Vice President and Chief Financial Officer, Darren Snellgrove, has filed an initial Form 3 statement of beneficial ownership. This administrative filing establishes his insider status but reports no buy, sell, or derivative transactions. The document indicates that no securities are beneficially owned by Snellgrove at this time.
Natixis Advisors LLC Has $6.68 Million Holdings in Halozyme Therapeutics, Inc. $HALO
Natixis Advisors LLC has reduced its stake in Halozyme Therapeutics by 13.1% in the fourth quarter, yet still holds 99,296 shares valued at $6.68 million. Despite this, analysts maintain a "Moderate Buy" consensus and increased price targets, with the company reporting strong quarterly results and positive FY2026 EPS guidance. However, recent insider selling by the CEO and COO has also been noted.
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Data And Analyst Buy Reaffirmation
Halozyme Therapeutics (HALO) has garnered fresh attention due to encouraging data from its partner argenx regarding a therapy using the ENHANZE delivery platform, alongside an analyst's reaffirmation of a positive stance. Despite steady share price gains and double-digit returns, the stock is considered 16.5% undervalued by analysts, with a fair value estimate of $85.78, though its current P/E ratio is higher than the industry average. The company's valuation is driven by anticipated growth from expanding partnerships and increased adoption of its subcutaneous biologics.
Quick ratio of Halozyme Therapeutics, Inc. – XETR:RV7
This article provides financial information for Halozyme Therapeutics, Inc. (XETR:RV7), specifically focusing on its quick ratio. It presents a table showing period values, changes, and percentage changes related to this financial metric. The content appears to be a stub or a section from a larger financial data page on TradingView.
TD Asset Management Inc Lowers Position in Halozyme Therapeutics, Inc. $HALO
TD Asset Management Inc. reduced its stake in Halozyme Therapeutics by 10% in the fourth quarter of 2025, selling over 103,000 shares but still owning 931,704 shares valued at $62.7 million. Despite this, Halozyme reported strong first-quarter results for 2026, surpassing analyst expectations with $1.60 EPS and $376.7 million in revenue, marking a 42.2% year-over-year increase. Analysts maintain a "Moderate Buy" consensus with a target price of $81.60, viewing the company's future growth positively, although some insider selling was noted.
ETFs Investing in Halozyme Therapeutics, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Halozyme Therapeutics, Inc., providing a detailed overview of each fund. The data includes market value, weight of Halozyme stock within the ETF, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information aims to help investors identify ETFs that offer exposure to Halozyme Therapeutics, Inc. with diversified portfolios.
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Data And Analyst Buy Reaffirmation
Halozyme Therapeutics (HALO) is drawing attention after positive data for a therapy using its ENHANZE platform and an analyst's reaffirmed "Buy" rating. Despite recent stock gains, analysts believe Halozyme is 16.5% undervalued with a fair value of $85.78, though its current P/E ratio is higher than the industry average. The company's expanding partnerships and increasing royalty streams from launched subcutaneous biologics are expected to drive significant future revenue and EBITDA growth.
Halozyme Therapeutics(HALO.US) Officer Sells US$3.37 Million in Common Stock
A Halozyme Therapeutics (HALO.US) officer recently sold common stock valued at approximately US$3.37 million. This transaction indicates insider selling activity within the company.
What Halozyme Therapeutics (HALO)'s New ENHANZE Partner Data and Analyst Support Means For Shareholders
Halozyme Therapeutics received a boost from positive clinical data reported by partner argenx for a therapy using Halozyme's ENHANZE technology, along with reaffirmed analyst support. This development strengthens the investment narrative for Halozyme's licensing model, which relies on partners like argenx and GSK expanding the use of ENHANZE. The company's future revenue and stock performance are closely tied to the success of these collaborations, though concentration risk remains a factor for investors.
